Dendritic cell vaccines for leukemia patients (Q36752018)

16 August 2017

1 reference

title

Dendritic cell vaccines for leukemia patients (English)

1 reference

16 August 2017

1 reference

2

Iwona Hus

1 reference

16 August 2017

Anita Schmitt

1

1 reference

PubMed ID

17338648

16 August 2017

Michael Schmitt

series ordinal

3

1 reference

16 August 2017

1 March 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

1 reference

16 August 2017

7

1 reference

16 August 2017

3

1 reference

16 August 2017

275-283

1 reference

Immunobiology of dendritic cells

16 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Dendritic cells as vectors for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Dendritic cell immunotherapy: mapping the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Murine dendritic cell-induced tumor apoptosis is partially mediated by nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Graft-versus-leukemia reactions in allogeneic chimeras

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Immune enhancement and anti-tumour activity of IL-23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Large-Scale Immunomagnetic Selection of CD14+Monocytes to Generate Dendritic Cells for Cancer Immunotherapy: A Phase I Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Dendritic cells as therapeutic vaccines against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Dendritic-cell-based therapeutic vaccination against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Generation of in vitro B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotic tumor lysate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Immature, but not inactive: the tolerogenic function of immature dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Tolerogenic dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Dendritic Cell Function in Vivo during the Steady State: A Role in Peripheral Tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Expression of human leucocyte antigens and co-stimulatory molecules on blasts of patients with acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

Use of CpG oligodeoxynucleotides as immune adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.275

21 January 2018

Identifiers

DOI

10.1586/14737140.7.3.275

1 reference

16 August 2017

1 reference

PubMed ID

17338648